New from us—Facedrive: A $1B+ ESG Stock Promotion with a Hollow Core Business, Flailing Business Pivots and Multi-Million Dollar Payments to an Opaque BVI Entity; 95% Downside
recently went public with the core premise of being an “eco-friendly” ride hailing app allowing users to select electric vehicle or hybrid options.
EV excitement has fueled the stock to a ludicrous $1.4 billion market cap and an absurd 908x revenue multiple.
's already-limited Canada-based ridesharing business appears to have been dramatically impaired by COVID.
While the company claims 13,000 registered drivers on the platform, we estimate current active drivers at ~500-600 total, suggesting a 95% overstatement.
Facedrive has very few users, minimal resources, and no sustainable differentiator in ridesharing.
Uber or Lyft could easily add electric vehicle options if they ever felt it worthwhile to eliminate Facedrive’s supposed ‘niche’.
Rather than focusing on tackling just one resource-intensive highly competitive market like ridesharing, recently entered a second—food delivery.
We found Facedrive’s platform has a total of 17 restaurants compared to UberEats' 400,000 and GrubHub's 300,000
We called several of the “most popular” restaurants on the Facedrive Foods page. One didn't seem to have a working phone number, and two said they don’t use Facedrive anymore.
Facedrive even joined the COVID-hype train, launching a COVID contact tracing app. We reached out to their partner on the project who confirmed what appears to be overstatements of the projects’ publicly stated progress.
has spiked on a slew of buzzword-laden press releases, helped by stock promoters who received payment through an opaque newly-renamed BVI-registered entity.
The site admits in its disclaimers that stocks it touts often plunge after their promotion cycle ends
In June 2020, paid $8.2M to an opaque newly named BVI entity for 1 month of “marketing” services.
This is the largest promotion payment we have ever seen and was greater than Facedrive’s entire operating budget over the last year.
Additionally, the company has engaged in multiple related party transactions. Its 2019 filing statement detailed paying 4 entities controlled by its CEO, representing approximately 24% of its 2019 operating expenses.
We do not think 's core business is viable & we find its “marketing” and related party spends to be alarming.
We have serious doubts about the veracity of the company’s claims relating to its ill-conceived side projects that appear hastily thrown together for PR value
's CEO has a history that bodes poorly. He was Chairman/CEO of another a public company, Creative Vistas, which saw its shares precipitously plummet by ~99%.
We believe this “story” stock is heading toward a hard repricing, as we see de minimis overall value in the company’s operations.
Our 1-year price target for is CAD $0.70, representing 95% downside
$EQIX is an $80 billion market cap data center REIT with over 260 facilities globally.
It has 10,000+ customers, ranging from small businesses to large cloud “hyperscaler” providers like Amazon, Microsoft and Google.
(2/x)
Even if you ignore our findings & take the financials of $EQIX at face value, the company trades at elevated levels; an ~86% premium to its peers on a price to forward AFFO basis and a ~59% premium on a price to forward FFO basis.
Our 4-month investigation into Temenos, involving interviews with 25 former employees, including senior leaders at the company, uncovered hallmarks of manipulated earnings and major accounting irregularities.
(2/n)
This includes evidence of roundtripped revenue, sham partnerships, rampant pulling forward of contract renewals, backdated contracts, excessive capitalization of seemingly non-existent R&D investments, and other classic accounting red flags.
$RENB is a biotech company with several preclinical drug candidates that is “committed to curing people with cancers and infectious diseases”.
Weeks ago, it voted to merge with “AI Health” company GEDi Cube, giving the company a pro-forma diluted market cap of ~$567m.
(2/n)
CEO Dr. Mark Dybul has a prestigious background:
(i) serving under Anthony Fauci at the National Institute of Health (NIH)
(ii) as Executive Director of the Global Fund to Fight AIDS, Tuberculosis, and Malaria and
(iii) as a tenured professor at Georgetown University
LifeStance is a $2.3 billion market cap mental health provider with 6,400 clinicians located across 33 U.S. states.
The company has grown its clinician base at 18% per year in a behavioral health market forecasted to grow ~5% per year until 2030. (2/n)
$LFST trades at a ~23% premium to its peers in the behavioral health industry, despite reporting in its most recent Q3 ’23 report: $188 million in losses over the last twelve months, $482 million in debt and lease obligations and a $716 million accumulated deficit.
In its complaint, the SEC alleges Mmobuosi and other defendants “booked billions of dollars’ worth of fictitious transactions through two Nigerian subsidiary companies Mmobuosi founded and controls”.
The complaint called Tingo Mobile a “sham” and “a fiction”, alleging that claimed assets, revenues, expenses, customers, and suppliers of Tingo Mobile were “virtually entirely fabricated” – and that the public co’s that control it have been “perpetrating an ongoing fraud”.